MicroRNA-1225-5p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of β-catenin signaling

Oncotarget

Volumn 7, Issue 4, 2016, Pages 4647-4663

  Zheng, Haiyin ^a   Zhang, Fuxing ^a,b   Lin, Xinjian ^a,c   Huang, Changming ^a   Zhang, Yiqin ^a   Li, Yun ^a   Lin, Jianyin ^a   Chen, Wannan ^a   Lin, Xu ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Gastric cancer; Insulin receptor substrate 1; microRNA; MicroRNA 1225 5p; catenin

Indexed keywords

BETA CATENIN; INSULIN RECEPTOR SUBSTRATE 1; MICRORNA; MICRORNA 1225 5P; UNCLASSIFIED DRUG; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; MESSENGER RNA; MIRN1225 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA EXTRACTION; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; UPREGULATION; ADENOCARCINOMA; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL MOTION; DRUG SCREENING; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; STOMACH TUMOR; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN RECEPTOR SUBSTRATE PROTEINS; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84957999033     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6615     Document Type: Article

References (46)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893-2917.
2. Yang L. Incidence and mortality of gastric cancer in China. World journal of gastroenterology: WJG. 2006; 12:17-20.
3. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008; 9:279-287.
4. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciardiello F and De Vita F. Treatment of gastric cancer. World journal of gastroenterology: WJG. 2014; 20:1635-1649.
5. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev. 2000; 26:243-255.
6. Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y and Oue N. Molecular pathology of gastric cancer: research and practice. Pathol Res Pract. 2011; 207:608-612.
7. Ambros V. The functions of animal microRNAs. Nature. 2004; 431:350-355.
8. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB. Prediction of mammalian microRNA targets. Cell. 2003; 115:787-798.
9. Hata A and Lieberman J. Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal. 2015; 8:2005825.
10. Esquela-Kerscher A and Slack FJ. Oncomirs-microRNAs with a role in cancer. Nature reviews Cancer. 2006; 6:259-269.
11. Shrestha S, Hsu SD, Huang WY, Huang HY, Chen W, Weng SL and Huang HD. A systematic review of microRNA expression profiling studies in human gastric cancer. Cancer Med. 2014; 3:878-888.
12. Zhang Z, Li Z, Li Y and Zang A. MicroRNA and signaling pathways in gastric cancer. Cancer Gene Ther. 2014; 21:305-316.
13. Motoyama K, Inoue H, Mimori K, Tanaka F, Kojima K, Uetake H, Sugihara K and Mori M. Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. International journal of oncology. 2010; 36:1089-1095.
14. Wang Z, Cai Q, Jiang Z, Liu B, Zhu Z and Li C. Prognostic role of microRNA-21 in gastric cancer: a meta-analysis. Med Sci Monit. 2014; 20:1668-1674.
15. Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W, Xiao S and Lu H. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest. 2008; 88:1358-1366.
16. Cui H, Wang L, Gong P, Zhao C, Zhang S, Zhang K, Zhou R, Zhao Z and Fan H. Deregulation between miR-29b/c and DNMT3A is associated with epigenetic silencing of the CDH1 gene, affecting cell migration and invasion in gastric cancer. PLoS One. 2015; 10.
17. Gong J, Li J, Wang Y, Liu C, Jia H, Jiang C, Luo M, Zhao H, Dong L, Song W, Wang F, Wang W, Zhang J, et al. Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer. Carcinogenesis. 2014; 35:497-506.
18. Wang Y, Liu C, Luo M, Zhang Z, Gong J, Li J, You L, Dong L, Su R, Lin H, Ma Y, Wang F, Chen J, et al. Chemotherapy-Induced miRNA-29c/Catenin-delta Signaling Suppresses Metastasis in Gastric Cancer. Cancer research. 2015; 75:1332-1344.
19. Dearth RK, Cui X, Kim HJ, Hadsell DL and Lee AV. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle. 2007; 6:705-713.
20. Geng Y, Ju Y, Ren F, Qiu Y, Tomita Y, Tomoeda M, Kishida M, Wang Y, Jin L, Su F, Wei C, Jia B, Li Y, et al. Insulin receptor substrate 1/2 (IRS1/2) regulates Wnt/beta-catenin signaling through blocking autophagic degradation of dishevelled2. J Biol Chem. 2014; 289:11230-11241.
21. Han TS, Hur K, Xu G, Choi B, Okugawa Y, Toiyama Y, Oshima H, Oshima M, Lee HJ, Kim VN, Chang AN, Goel A and Yang HK. MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1. Gut. 2015; 64:203-214.
22. Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock MD, Braicu C, Pileczki V, Vincent K, Pichler M, Stiegelbauer V, et al. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut. 2015; 24:2015-309372.
23. Shi C, Yang Y, Xia Y, Okugawa Y, Yang J, Liang Y, Chen H, Zhang P, Wang F, Han H, Wu W, Gao R, Gasche C, Qin H, Ma Y and Goel A. Novel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer. Gut. 2015; 20:2014-308455.
24. Gailhouste L, Gomez-Santos L, Hagiwara K, Hatada I, Kitagawa N, Kawaharada K, Thirion M, Kosaka N, Takahashi RU, Shibata T, Miyajima A and Ochiya T. miR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells. Hepatology. 2013; 58:1153-1165.
25. Pan L, Huang S, He R, Rong M, Dang Y and Chen G. Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues. Eur J Med Res. 2014; 19:014-0068.
26. Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, Sato A, Kondo S, Kojima T, Deguchi T and Ito M. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. The Journal of biological chemistry. 2010; 285:19076-19084.
27. Murata T, Takayama K, Katayama S, Urano T, Horie-Inoue K, Ikeda K, Takahashi S, Kawazu C, Hasegawa A, Ouchi Y, Homma Y, Hayashizaki Y and Inoue S. miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis. 2010; 13:356-361.
28. Takahashi M, Cuatrecasas M, Balaguer F, Hur K, Toiyama Y, Castells A, Boland CR and Goel A. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One. 2012; 7:3.
29. Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng H and Lai M. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell death and differentiation. 2011; 18:1702-1710.
30. Xia J, Guo X, Yan J and Deng K. The role of miR-148a in gastric cancer. Journal of cancer research and clinical oncology. 2014; 140:1451-1456.
31. Delpu Y, Lulka H, Sicard F, Saint-Laurent N, Lopez F, Hanoun N, Buscail L, Cordelier P and Torrisani J. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool. PLoS One. 2013; 8:31.
32. Zhang R, Li M, Zang W, Chen X, Wang Y, Li P, Du Y, Zhao G and Li L. MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. Tumour Biol. 2014; 35:837-844.
33. Lombard AP, Mooso BA, Libertini SJ, Lim RM, Nakagawa RM, Vidallo KD, Costanzo NC, Ghosh PM and Mudryj M. miR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1. Mol Carcinog. 2015; 11:22319.
34. Zhou X, Zhao F, Wang ZN, Song YX, Chang H, Chiang Y and Xu HM. Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol Rep. 2012; 27:447-454.
35. Jiang F, Li Y, Mu J, Hu C, Zhou M, Wang X, Si L, Ning S and Li Z. Glabridin inhibits cancer stem cell-like properties of human breast cancer cells: An epigenetic regulation of miR-148a/SMAd2 signaling. Mol Carcinog. 2015; 15:22333.
36. Tao S, He H, Chen Q and Yue W. GPER mediated estradiol reduces miR-148a to promote HLA-G expression in breast cancer. Biochemical and biophysical research communications. 2014; 451:74-78.
37. Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C and Liu Z. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg. 2010; 14:1170-1179.
38. Guo SL, Peng Z, Yang X, Fan KJ, Ye H, Li ZH, Wang Y, Xu XL, Li J, Wang YL and Teng Y. miR-148a promoted cell proliferation by targeting p27 in gastric cancer cells. Int J Biol Sci. 2011; 7:567-574.
39. Yan J, Guo X, Xia J, Shan T, Gu C, Liang Z, Zhao W and Jin S. MiR-148a regulates MEG3 in gastric cancer by targeting DNA methyltransferase 1. Med Oncol. 2014; 31:014-0879.
40. Sharma T, Hamilton R and Mandal CC. miR-214: a potential biomarker and therapeutic for different cancers. Future Oncol. 2015; 11:349-363.
41. Liu D, Tao T, Xu B, Chen S, Liu C, Zhang L, Lu K, Huang Y, Jiang L, Zhang X, Huang X, Han C and Chen M. MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6). Biochemical and biophysical research communications. 2014; 445:151-156.
42. Wu X, Xi X, Yan Q, Zhang Z, Cai B, Lu W and Wan X. MicroRNA-361-5p facilitates cervical cancer progression through mediation of epithelial-to-mesenchymal transition. Med Oncol. 2013; 30:751.
43. Porter HA, Perry A, Kingsley C, Tran NL and Keegan AD. IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. Cancer Lett. 2013; 338:239-248.
44. Su W, Xu M, Chen X, Nie L, Chen N, Gong J, Zhang M, Su Z, Huang L and Zhou Q. MiR200c targets IRS1 and suppresses prostate cancer cell growth. Prostate. 2015; 75:855-862.
45. Wang Y, Hu C, Cheng J, Chen B, Ke Q, Lv Z, Wu J and Zhou Y. MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling. Biochemical and biophysical research communications. 2014; 446:1255-1260.
46. Zhou Y, Feng X, Liu YL, Ye SC, Wang H, Tan WK, Tian T, Qiu YM and Luo HS. Down-regulation of miR-126 is associated with colorectal cancer cells proliferation, migration and invasion by targeting IRS-1 via the AKT and ERK1/2 signaling pathways. PLoS One. 2013; 8.